Open AccessA lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report
Author(s) -
Fangye Xu,
Chunmei Xiao,
Weijie Sun,
Yuange He,
Roberto Chalela,
Ken Masuda,
Paola Ulivi,
Kai Shen,
Qianwen Shao,
Jiali Xu,
Lianke Liu
Publication year - 2022
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm-22-3582
Subject(s) - ros1 , germline , cancer research , mutation , adenocarcinoma , medicine , oncology , biology , genetics , cancer , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom